Although FAD2 + AraC2, has significantly increased anti-proliferative effect as compared to FAD2 in both AML and normal CD34 + samples, this is fully accounted for by the known cytotoxic effects of AraC (Fig. 4B, E). Here, CD34 is linked to acute myeloid leukemia.